Skip to main content

Table 6 MTHFR diplotypes and breast cancer survival

From: Association of MTHFR gene polymorphisms with breast cancer survival

  HR (95% CI)1 p-value
MTHFR diplotypes (n = 198)2   
   CC/AA + CC/AC (high enzyme activity) 1  
   Others (low enzyme activity) 0.61 (0.3–1.22) 0.16
ER-negative (n = 84)   
   CC/AA + CC/AC 1  
   Others 0.47 (0.19–1.20) 0.11
ER-positive (n = 114)   
   CC/AA + CC/AC 1  
   Others C 0.83 (0.27–2.59) 0.75
African-American (n = 121)   
   CC/AA + CC/AC 1  
   Others 0.22 (0.05–0.96) 0.04
Caucasian (n = 77)   
   CC/AA + CC/AC 1  
   Others 1.19 (0.36–3.96) 0.78
No Chemotherapy (n = 81)   
   CC/AA + CC/AC 1  
   Others 0.54 (0.15–1.96) 0.35
Chemotherapy (n = 117)   
   CC/AA + CC/AC 1  
   Others 0.59 (0.25–1.38) 0.23
  1. 1 Cox Proportional-Hazards regression with adjustments for age at diagnosis, race, BMI, estrogen receptor, TNM stage, and chemotherapy. Time at risk and number of events for the strata are shown in Tables 4 and 5.
  2. 2 MTHFR diplotypes were generated from the C677T and A1298C genotypes using the information shown in Table 3. Diplotypes were dichotomized into a group that encodes a high activity enzyme [CC(677) and AA or AC(1298)] and a group that encodes a low activity enzyme (all other diplotypes).